Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a Medium interview, Professor Matthew Wood, a professor of Neuroscience in the Department of Paediatrics, talks about his work and the advances that a new Rare Diseases Centre could herald for the future of rare disease and genetics.

On Rare Diseases Day 2019, the University of Oxford and Harrington Discovery Institute at University Hospitals have announced a new affiliation to advance therapies for rare diseases.

The Oxford-Harrington Rare Disease Centre will bring together the capabilities, resources and expertise of both institutions to deliver new treatments for rare diseases, for which therapeutic options are lacking.

More than 350 million people worldwide are living with a rare disease, and approximately 50 percent of those are children. Here, we speak to Professor Matthew Wood, a professor of Neuroscience in the Department of Paediatrics, about his work and the advances that a new Rare Diseases Centre could herald for the future of rare disease and genetics.

Read more (Medium website)

Oxford-Harrington Rare Disease Centre news story (University of Oxford website)

 

 

Similar stories

Children’s pain ‘swept under the carpet for too long’ – Lancet Commission

Neuroimaging Publication Research

The launch of Lancet Child and Adolescent Health Commission - the first ever to address paediatric pain - aims to raise the profile of children’s pain from early years to early adulthood.

Oxford COVID-19 vaccine begins human trial stage

COVID-19 Recruitment Research Vaccinology

University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.

Funding for new COVID-19 studies awarded to OVG's project on infectious disease immunity in children

Awards & Appointments COVID-19 Research Vaccinology

Five projects from across Oxford University's Medical Sciences Division, including a project led by Professor Matthew Snape from the Oxford Vaccine Group, are among twenty-one new studies into the novel coronavirus which have been funded by the UK government.

Visualising COVID-19 outbreak

COVID-19 Neuroimaging Research Research Methods

Paediatric Neuroimaging researcher provides real-time case information on epidemiological data from the COVID-19 outbreak.

Oxford COVID-19 vaccine programme opens for clinical trial recruitment

COVID-19 Research Vaccinology

University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won’t be ready for some weeks still.

COVID-19 vaccine development

COVID-19 Research Vaccinology

A vaccine candidate for COVID-19 has been identified by researchers from the Oxford Vaccine Group and Oxford's Jenner Institute.